Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.Smith, B.D., Kaufman, M.D., Lu, W.P., Gupta, A., Leary, C.B., Wise, S.C., Rutkoski, T.J., Ahn, Y.M., Al-Ani, G., Bulfer, S.L., Caldwell, T.M., Chun, L., Ensinger, C.L., Hood, M.M., McKinley, A., Patt, W.C., Ruiz-Soto, R., Su, Y., Telikepalli, H., Town, A., Turner, B.A., Vogeti, L., Vogeti, S., Yates, K., Janku, F., Abdul Razak, A.R., Rosen, O., Heinrich, M.C., Flynn, D.L.
(2019) Cancer Cell 35: 738-751.e9
- PubMed: 31085175
- DOI: 10.1016/j.ccell.2019.04.006
- Structures With Same Primary Citation
- PubMed Abstract:
Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant ...
Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in gastrointestinal stromal tumors (GISTs), in which the heterogeneity of drug-resistant KIT mutations is a major challenge. Ripretinib is a "switch-control" kinase inhibitor that forces the activation loop (or activation "switch") into an inactive conformation. Ripretinib inhibits all tested KIT and PDGFRA mutants, and notably is a type II kinase inhibitor demonstrated to broadly inhibit activation loop mutations in KIT and PDGFRA, previously thought only achievable with type I inhibitors. Ripretinib shows efficacy in preclinical cancer models, and preliminary clinical data provide proof-of-concept that ripretinib inhibits a wide range of KIT mutants in patients with drug-resistant GISTs.
Deciphera Pharmaceuticals, Inc., Waltham, MA 02451, USA. Electronic address: firstname.lastname@example.org.